Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir

Journal of Viral Hepatitis

Volumn 19, Issue 3, 2012, Pages 213-219

  Pan, C Q ^a   Hu, K Q ^b   Yu, A S ^c   Chen, W ^d   Bunchorntavakul, C ^e,f   Reddy, K R ^f  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Pacific Gastroenterology and Endoscopy San Jose   (United States)

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^e RANGSIT UNIVERSITY   (Thailand)

^f HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antiviral; entecavir; Hepatitis B; inadequate response; nucleoside analogue; resistance; suboptimal response; tenofovir; treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2A; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GENE MUTATION; GENOTYPE; HEPATITIS B; HUMAN; MALE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; TREATMENT RESPONSE;

ADENINE; ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHONIC ACIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857366393     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2011.01533.x     Document Type: Review

References (31)

1. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ,. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686. (Pubitemid 43374518)
2. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F,. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003; 37: 1309-1319. (Pubitemid 36667310)
3. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588. (Pubitemid 350294224)
4. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009; 51: 11-20.
5. Nguyen MH, Keeffe EB,. Chronic hepatitis B: early viral suppression and long-term outcomes of therapy with oral nucleos(t)ides. J Viral Hepat 2009; 16: 149-155.
6. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007; 5: 890-897. (Pubitemid 47127032)
7. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242.
8. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
9. Woo G, Tomlinson G, Nishikawa Y, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-1229.
10. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437-1444. (Pubitemid 350029745)
11. Colonno R, Rose R, Levine S, et al. Entecavir two year resistance update: no resistance observed in nucleoside naive patients and low frequency resistance emergence in lamivudine refractory patients. Hepatology 2005; 42: 573A-574A.
12. Sherman M, Yurdaydin C, Simsek H, et al. Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology 2008; 48: 99-108. (Pubitemid 351975535)
13. van Bommel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 2010; 51: 73-80.
14. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011; 60: 247-254.
15. van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-325. (Pubitemid 44214870)
16. Villet S, Ollivet A, Pichoud C, et al. Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient. J Hepatol 2007; 46: 531-538. (Pubitemid 46201724)
17. Pan C, Hu K,. Excellent treatment response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir monotherapy. Hepatology 2008; 48: 725A.
18. Ghany MG, Doo EC,. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174-S184.
19. Leemans WF, Niesters HG, van der Eijk AA, Janssen HL, Schalm SW, de Man RA,. Selection of an entecavir-resistant mutant despite prolonged hepatitis B virus DNA suppression, in a chronic hepatitis B patient with preexistent lamivudine resistance: successful rescue therapy with tenofovir. Eur J Gastroenterol Hepatol 2008; 20: 773-777.
20. Carrouee-Durantel S, Durantel D, Werle-Lapostolle B, et al. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants. Antivir Ther 2008; 13: 381-388. (Pubitemid 352016731)
21. Zhang QH, Yang J, He Y, Liu F, Wang JP, Davey AK,. Food effect on the pharmacokinetics of entecavir from dispersible tablets following oral administration in healthy Chinese volunteers. Arzneimittelforschung 2010; 60: 640-644.
22. Yan JH, Bifano M, Olsen S, et al. Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects. J Clin Pharmacol 2006; 46: 1250-1258. (Pubitemid 44564354)
23. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS,. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011; 54: 12-18.
24. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020. (Pubitemid 43357805)
25. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
26. Baldick CJ, Eggers BJ, Fang J, et al. Hepatitis B virus quasispecies susceptibility to entecavir confirms the relationship between genotypic resistance and patient virologic response. J Hepatol 2008; 48: 895-902.
27. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005; 129: 1198-1209. (Pubitemid 41446860)
28. Fung SK, Mazzulli T, Sherman M, Popovic V, Ramos M, Sablon E,. Pre-existing antiviral resistance mutations among treatment-naive HBV patients can be detected by a sensitive line probe assay. J Hepatol 2008; 48: S256.
29. Han Y, Huang LH, Liu CM, et al. Characterization of hepatitis B virus reverse transcriptase sequences in Chinese treatment naive patients. J Gastroenterol Hepatol 2009; 24: 1417-1423.
30. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455.
31. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naive patients with a partial virological response. Hepatology 2011; 54: 443-451.